A new cancer vaccine targeting KRAS gene mutations shows promise in preventing pancreatic and colorectal cancer recurrence in ...

Dr. Zev Wainberg of UCLA recently spoke with CURE about trial results concerning the cancer vaccine ELI-002 2P.

An off-the-shelf cancer vaccine that targets KRAS mutations induced T-cell responses and was associated with impressive ...

An 'off-the-shelf' vaccine may help prevent or delay cancer recurrence in people with hard-to-treat colorectal or pancreatic ...

A new study reveals promising results for a vaccine targeting colorectal and pancreatic cancers. Researchers from the ...

New Phase I trial data finds that people who responded to ELI-002 survived longer and stayed cancer-free longer than usual.

A new 'off-the-shelf' vaccine with the catchy name ELI-002 2P offers fresh hope for individuals affected by these deadly ...

A novel vaccine designed to target one of the most common cancer-driving mutations in patients with pancreatic and colorectal ...

Elicio's mKRAS-targeting cancer vaccine reduced the risk of death by 77% by activating the anti-tumour mechanisms of key ...

A novel cancer vaccine that stimulates the immune system to target one of the most common cancer-driving mutations has shown ...

A new vaccine aimed at a common cancer gene mutation could help stop aggressive pancreatic cancers from coming back, a small ...

A new pancreatic cancer vaccine has appeared to slow disease progression and increase survival for patients in an early trial ...